945 related articles for article (PubMed ID: 32744738)
21. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
[TBL] [Abstract][Full Text] [Related]
24. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
25. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
[TBL] [Abstract][Full Text] [Related]
26. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
Dickinson M; Martinez-Lopez J; Jousseaume E; Yang H; Chai X; Xiang C; Wang T; Zhang J; Ramos R; Schuster SJ; Fowler N
Leuk Lymphoma; 2024 Mar; 65(3):323-332. PubMed ID: 38179688
[TBL] [Abstract][Full Text] [Related]
28. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
[TBL] [Abstract][Full Text] [Related]
29. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
[TBL] [Abstract][Full Text] [Related]
30. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
31. Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel.
Terao T; Kitamura W; Fujii N; Asada N; Kamoi C; Fujiwara K; Kondo K; Matsubara C; Hayashino K; Seike K; Fujiwara H; Ennishi D; Nishimori H; Fujii K; Matsuoka KI; Maeda Y
Transplant Cell Ther; 2023 Sep; 29(9):573.e1-573.e8. PubMed ID: 37394114
[TBL] [Abstract][Full Text] [Related]
32. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
33. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma.
Ghanem B
Invest New Drugs; 2023 Oct; 41(5):710-718. PubMed ID: 37572232
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
37. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
Steiner RE; Banchs J; Koutroumpakis E; Becnel M; Gutierrez C; Strati P; Pinnix CC; Feng L; Rondon G; Claussen C; Palaskas N; Karimzad K; Ahmed S; Neelapu SS; Shpall E; Wang M; Vega F; Westin J; Nastoupil LJ; Deswal A
Haematologica; 2022 Jul; 107(7):1555-1566. PubMed ID: 34758610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
